Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 11 2021 - 6:45AM
Heidelberg, Germany, January 11, 2021 –
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that its Chief Executive Officer, Dr.
Adi Hoess, will present at the 39th Annual J.P. Morgan Healthcare
Conference on Thursday, January 14, 2021 at 7:30 a.m. Eastern
Standard Time.
A live webcast of the presentation may be accessed on Affimed’s
website at https://www.affimed.com/investors/webcasts_cp/ and will
be available for 30 days following the event. For more information
or to schedule a one-on-one meeting with Affimed management, please
contact Alex Fudukidis via email at a.fudukidis@affimed.com or
phone at +1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Investor Relations Contact
Alex Fudukidis Head of Investor Relations E-Mail:
a.fudukidis@affimed.com Tel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024